Enlimomab is a monoclonal antibody that was developed for therapeutic use, particularly in the context of autoimmune diseases and inflammatory conditions. It is designed to target specific immune system components, thereby modulating immune responses. The CAS number 142864-19-5 identifies this substance uniquely in chemical databases. Enlimomab is characterized by its ability to bind to certain cell surface proteins, which can influence cellular signaling pathways and immune cell activity. This mechanism of action makes it a candidate for treating conditions such as rheumatoid arthritis and other inflammatory disorders. The antibody's structure typically consists of heavy and light chains, forming a Y-shaped molecule that facilitates its binding to antigens. As with many monoclonal antibodies, its efficacy and safety profile are determined through clinical trials, and it may exhibit side effects related to immune modulation. Overall, Enlimomab represents a significant advancement in targeted therapies within the field of immunology.

Enlimomab

142864-19-5: Enlimomab is a monoclonal antibody that was developed for therapeutic use, particularly in the context of autoimmune diseases and inflammatory conditions. It is designed to target specific immune system components, thereby modulating immune responses. The CAS number 142864-19-5 identifies this substance uniquely in chemical databases. Enlimomab is characterized by its ability to bind to certain cell surface proteins, which can influence cellular signaling pathways and immune cell activity. This mechanism of action makes it a candidate for treating conditions such as rheumatoid arthritis and other inflammatory disorders. The antibody's structure typically consists of heavy and light chains, forming a Y-shaped molecule that facilitates its binding to antigens. As with many monoclonal antibodies, its efficacy and safety profile are determined through clinical trials, and it may exhibit side effects related to immune modulation. Overall, Enlimomab represents a significant advancement in targeted therapies within the field of immunology.

murine intercellular adhesion molecule-1 (ICAM-1) antibody

<p>Enlimomab (BI-RR 0001), a mouse IgG2a antibody, blocks leukocyte binding to ICAM-1, reducing inflammation and used in stroke research.</p>

CAS 142864-19-5

Enlimomab

Enlimomab

Ref: 3D-CLA1097

Enlimomab

Ref: TM-T76841